New to The Street TV Announces its Business Guest Interviews, Episode #388 Airs on Bloomberg TV, Saturday, September 24, 2022, at 6:00 PM ET as Sponsored Programming
23 sept. 2022 10h15 HE | FMW Media Works Corp
NEW YORK, Sept. 23, 2022 (GLOBE NEWSWIRE) --  FMW Media’s New to The Street TV announces broadcasting its sponsored program business show Saturday, September 24, 2022, on Bloomberg TV at 6:00 PM ET....
Straits Research Pvt Ltd
Fungal Keratitis Treatment Market Size is projected to reach USD 1.32 Billion by 2030, growing at a CAGR of 6%: Straits Research
14 juil. 2022 13h00 HE | Straits Research
New York, United States, July 14, 2022 (GLOBE NEWSWIRE) -- The fungal keratitis treatment market is driven by the increasing prevalence of such diseases worldwide, rising awareness of the potential...
MicroGenDX First Independent Commercial Lab in US Offering NGS for Infections to Appeal Directly to Patients
24 janv. 2022 18h07 HE | Microgen Diagnostics
ORLANDO, Fla., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Using national TV, radio, and web media campaigns, Microgen Diagnostics will be the first independent commercial lab in the U.S. to appeal directly...
What's Wrong Wellness: One Mother's Chilling Medical Discovery That Could Be Impacting Many Families
30 sept. 2021 06h00 HE | What's Wrong Wellness
NASHVILLE, Tenn., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Morgan James Publishing's new release What's Wrong With My Child?: One Mother's Desperate Quest to Uncover What Was Really Wrong With Her Family...
July 30, 2021 - ROSEN LOGO.jpg
CRMD BREAKING NEWS: ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages CorMedix Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – CRMD
17 août 2021 12h03 HE | The Rosen Law Firm PA
NEW YORK, Aug. 17, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CorMedix Inc. (NASDAQ: CRMD) between July 8, 2020 and...
DEINOVE is now ready to start Phase II clinical trial for its antibiotic compound DNV3837
16 mai 2019 12h30 HE | Deinove
DEINOVE is now ready to start Phase II clinical trial for its antibiotic compound DNV3837 Having reached a sufficient number of clinical centers, Phase II clinical trial testing the antibiotic...
Entasis Therapeutics Initiates Global Phase 3 Pivotal Trial of ETX2514SUL for Patients with Carbapenem-Resistant Acinetobacter Infections
04 avr. 2019 08h00 HE | Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., April 04, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel antibacterials to treat serious...
Earth Science Tech, Inc. (ETST) Announces Strategic Partnerships to Market Hygee™ and Address Global Epidemic
08 janv. 2019 08h00 HE | Earth Science Tech, Inc.
DORAL, Florida, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and...
CidaraLogo (1).jpg
Cidara Therapeutics Announces Pricing of $20 Million Private Placement of Common Stock
19 oct. 2017 09h00 HE | Cidara Therapeutics, Inc.
SAN DIEGO, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the pricing...
National Patient Safety Foundation Joins with CDC and Others to Celebrate Annual Get Smart About Antibiotics Week, November 14-20, 2016
02 nov. 2016 09h41 HE | The National Patient Safety Foundation
BOSTON, Nov. 2, 2016 (GLOBE NEWSWIRE) -- The National Patient Safety Foundation (NPSF), a central voice for patient safety since 1997, is proud to partner with the Centers for Disease Control and...